Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05051241Phase 1Completed

A Study of GFH018 in Patients With Advanced Solid Tumors

Role: lead

NCT05618691Phase 2Withdrawn

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

Role: lead

NCT05991362Phase 1Completed

A Phase I Study of GFH312 in Healthy Chinese Subjects

Role: lead

NCT05165849Phase 1Withdrawn

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Role: lead

All 4 trials loaded